TD Private Client Wealth’s Apogee Therapeutics APGE Stock Holding History

TD Private Client Wealth’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-18	Closed	-$2.39K	–	1775
2026 Q2	$2.39K	Hold	18	–	–	﹤0.01%	1336
2026 Q1	$1.52K	Hold	18	–	–	﹤0.01%	1328
2025 Q4	$1.36K	Hold	18	–	–	﹤0.01%	1324
2025 Q3	$715	Buy	+18	New	+$687	﹤0.01%	1393

Other funds holding APGE

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return

TD Private Client Wealth's APGE Position: Q3 2026 in Review

TD Private Client Wealth sold out of Apogee Therapeutics (APGE) in Q3 2026, closing a stake of 18 shares — an estimated $2.39K sold.

TD Private Client Wealth first reported a position in APGE in Q3 2025 and held it in 4 quarters. The position peaked at $2.39K in Q2 2026. 2 funds tracked by Wall St. Rank hold APGE as of Q3 2026.

TD Private Client Wealth reported no remaining Apogee Therapeutics position as of Q3 2026 after selling out during the quarter.
TD Private Client Wealth sold 18 Apogee Therapeutics shares in Q3 2026, an estimated $2.39K.
TD Private Client Wealth first reported a position in Apogee Therapeutics in Q3 2025 and held it in 4 quarters.
TD Private Client Wealth's Apogee Therapeutics position peaked at $2.39K in Q2 2026.
2 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q3 2026.

Based on TD Private Client Wealth's 13F filing for Q3 2026, filed 28 Oct 2026.